Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details Narrative)

v3.21.2
Intangible Assets (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Finite-Lived Intangible Assets [Line Items]    
Amortization expense $ 397,664 $ 397,664
Future amortization expense 790,000  
Future amortization expense, annual periods thereafter 788,000  
License Rights [Member] | CoNCERT Pharmaceuticals, Inc [Member]    
Finite-Lived Intangible Assets [Line Items]    
Purchase price 8,000,000  
Transaction cost 1,782  
Recognition of deferred tax liability 3,037,147  
Intangible asset, tax basis $ 1,782